AEterna Zentaris (NASDAQ: AEZS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AEterna Zentaris (NASDAQ: AEZS)

AEZS 2.720

-11.7%

Sep 3 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Gary Mohilner	12/17/2012 4:24:50 PM
	of 22

Anyone here still following AEZS. Other than the fact that nearly all they do is taking longer than investors think it should, there are still many signs of progress, and few problems that can't be overcome. 2012 certainly wasn't a banner year for AEZS, but even if everything doesn't go perfectly, 2013 could be. I believe that all who thought AEZS should abandon Perifosine are beginning to see the many reason's they didn't. In fact, Perifosine failing and being returned to AEZS by KERX may prove to be worth far more to AEZS in the long run than had the failed trial led to an approval. As for all of AEZS's other drugs, blockbuster potential is possible for all, but things must go their way. Take AEZS-130, it's a niche drug in diagnosing HGH deficiency, but if cancer cachexia trials go well, that could make it worth billions. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext